Janssen’s latest move against Amgen highlights shifting pharma patent strategies
J&J subsidiary makes innovative use of IP acquired in $6.5 billion Momenta acquisition
J&J subsidiary makes innovative use of IP acquired in $6.5 billion Momenta acquisition
The new long-term agreements with both 3D NAND memory manufacturers includes Adeia's hybrid bonding rights
The time and expense of launching an assertion programme in untested markets will limit the buyer’s ROI as well as incoming royalties
Survey of deals forms part of wider IAM Q1 2022 Special Report on patent transactions now available to subscribers
03 March 2022
ROI’s latest report on sales activity and reflections on 10 years of market tracking
02 March 2022
Some of the highest-value deals in intellectual property today are taking place in the burgeoning marketplace for revenue streams linked to pharmaceutical products
02 March 2022
Six things we learned about the transactions marketplace in a year that featured notable patent deals both big and small
02 March 2022
Staying on top of patent transactions activity is difficult, but can have significant implications for an organisation’s IP risk.
02 March 2022
I have nothing but good things to say about the company but it's time to move on and do something new, says Joseph Kessler
01 March 2022
Patent transactions involving former Samsung IP head reveal context of in-house chief’s move to the licensing sector – a big uptick in local standards development and dealmaking
24 February 2022
Numbers were up from 1,587 to 1,654 between 2020 and 2021, with the biggest Q4 deal involving IBM and the Open Invention Network
23 February 2022
Roivant’s most recent spinout shows that it is still on the hunt for deprioritised life sciences patents
22 February 2022
Unlock unlimited access to all IAM content